BioSpace News Archive

Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.

Epigenomics AG today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, the first and only FDA-approved blood test for colorectal cancer screening.

AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.

An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.

Study will be conducted at up to 20 leading transplant centers in the U.S.

Rentschler Biopharma SE announced today that Henning Gerschewski (44) will join the company as Vice President Manufacturing Science and Technology, effective January 01, 2019. He will head a highly experienced team of senior scientists with the goal of ensuring technical leadership in process development and technology transfer activities.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCA mutation (gBRCAm) and are eligible for first-line maintenance therapy with AstraZeneca’s PARP (poly ADP ribose polymerase) inhibitor, Lynparza®

Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis.

IDbyDNA, a metagenomics technology company providing more actionable Infectious Disease test results, today announced that it will present at the Digital Medicine and Medtech Showcase 2019, occurring January 7-9, 2019 at the Parc 55 in San Francisco

Current year-to-date revenues were $206,724,000, also up 6% compared to $194,907,000 for the same period a year ago.